

Performance in Delivery Q1 19-20

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In	Maximum Number Of Patients Agreed (Enter Same In	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/NW/0305	201856	A Phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of DYSPOUR® for the treatment of urinary incontinence in subjec	Number Agreed	4	4	Date Agreed	30/09/2019	3	01/10/2018	3	Recruitment Finished
17/NW/0698	233163	An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments	Number Agreed	1	1	Date Agreed	31/12/2019	0	31/12/2018	0	Recruitment Finished
18/SW/0162	248769	PICO 7 - A prospective follow up study to assess performance, safety and efficacy of the PICO 7 NPWT system for surgically closed incision sites and skin grafts	Number Agreed	4	4	Date Agreed	30/06/2019	5	21/05/2019	5	Recruitment Finished
17/NE/0174	224141	A PERFORMANCE EVALUATION STUDY OF ARQUER'S MCM5 ELISA TEST TO AID IN THE MONITORING OF BLADDER CANCER RECURRENCE	Number Agreed	60	60	Date Agreed	30/06/2019	73	30/06/2019	73	Recruitment Finished
15/NE/0278	183395	AZURE eyes - An open-label, randomized, active-controlled, parallel group, Phase-3b study of the efficacy, safety, and tolerability of 2mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neo	Number Agreed	4	4	Date Agreed	30/04/2019	3	23/10/2018	3	Recruitment Finished